Financhill
Buy
81

PDEX Quote, Financials, Valuation and Earnings

Last price:
$49.31
Seasonality move :
1.86%
Day range:
$46.46 - $50.00
52-week range:
$16.84 - $59.60
Dividend yield:
0%
P/E ratio:
24.83x
P/S ratio:
2.77x
P/B ratio:
5.09x
Volume:
58.7K
Avg. volume:
37.1K
1-year change:
185.4%
Market cap:
$161.9M
Revenue:
$53.8M
EPS (TTM):
$2.00

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PDEX
Pro-Dex
$18.5M $0.48 23.84% 147.37% $54.00
CATX
Perspective Therapeutics
-- -$0.30 -- -41.72% $15.58
VNRX
VolitionRX
$1M -$0.05 123.53% -51.52% $3.37
VTAK
Catheter Precision
$600K -$0.18 118.75% -11.57% --
WST
West Pharmaceutical Services
$707.5M $1.44 -1.45% -21.05% $286.12
XTNT
Xtant Medical Holdings
$32.3M -$0.02 9.96% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PDEX
Pro-Dex
$49.66 $54.00 $161.9M 24.83x $0.00 0% 2.77x
CATX
Perspective Therapeutics
$2.59 $15.58 $175.1M -- $0.00 0% 13.99x
VNRX
VolitionRX
$0.56 $3.37 $52M -- $0.00 0% 36.22x
VTAK
Catheter Precision
$0.38 -- $3.1M 0.44x $0.00 0% 1.03x
WST
West Pharmaceutical Services
$230.11 $286.12 $16.6B 34.40x $0.21 0.36% 5.86x
XTNT
Xtant Medical Holdings
$0.48 $1.75 $66.8M -- $0.00 0% 0.55x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PDEX
Pro-Dex
33.99% 3.333 10.75% 1.35x
CATX
Perspective Therapeutics
-- -3.661 -- --
VNRX
VolitionRX
-28.76% -0.785 8.83% 0.19x
VTAK
Catheter Precision
12% -2.395 128.21% 0.53x
WST
West Pharmaceutical Services
7.02% 1.553 0.92% 1.88x
XTNT
Xtant Medical Holdings
44.29% 0.232 55.45% 0.94x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PDEX
Pro-Dex
$5.1M $2.7M 15.21% 21.59% 16.61% -$4.7M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
VNRX
VolitionRX
-- -$5.8M -- -- -1217.88% -$5.5M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
WST
West Pharmaceutical Services
$273.6M $169.8M 16.88% 18.15% 21.92% $85.2M
XTNT
Xtant Medical Holdings
$16M -$1.9M -21.41% -35.34% -6.38% -$7K

Pro-Dex vs. Competitors

  • Which has Higher Returns PDEX or CATX?

    Perspective Therapeutics has a net margin of 12.15% compared to Pro-Dex's net margin of --. Pro-Dex's return on equity of 21.59% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    30.2% $0.61 $48.2M
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About PDEX or CATX?

    Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 8.74%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.58 which suggests that it could grow by 501.43%. Given that Perspective Therapeutics has higher upside potential than Pro-Dex, analysts believe Perspective Therapeutics is more attractive than Pro-Dex.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is PDEX or CATX More Risky?

    Pro-Dex has a beta of 0.682, which suggesting that the stock is 31.755% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.251, suggesting its more volatile than the S&P 500 by 25.149%.

  • Which is a Better Dividend Stock PDEX or CATX?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PDEX or CATX?

    Pro-Dex quarterly revenues are $16.8M, which are larger than Perspective Therapeutics quarterly revenues of --. Pro-Dex's net income of $2M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Pro-Dex's price-to-earnings ratio is 24.83x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.77x versus 13.99x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.77x 24.83x $16.8M $2M
    CATX
    Perspective Therapeutics
    13.99x -- -- -$15.1M
  • Which has Higher Returns PDEX or VNRX?

    VolitionRX has a net margin of 12.15% compared to Pro-Dex's net margin of -1226.82%. Pro-Dex's return on equity of 21.59% beat VolitionRX's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    30.2% $0.61 $48.2M
    VNRX
    VolitionRX
    -- -$0.07 -$17.8M
  • What do Analysts Say About PDEX or VNRX?

    Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 8.74%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 501.2%. Given that VolitionRX has higher upside potential than Pro-Dex, analysts believe VolitionRX is more attractive than Pro-Dex.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    VNRX
    VolitionRX
    2 1 0
  • Is PDEX or VNRX More Risky?

    Pro-Dex has a beta of 0.682, which suggesting that the stock is 31.755% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

  • Which is a Better Dividend Stock PDEX or VNRX?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PDEX or VNRX?

    Pro-Dex quarterly revenues are $16.8M, which are larger than VolitionRX quarterly revenues of $474.5K. Pro-Dex's net income of $2M is higher than VolitionRX's net income of -$5.8M. Notably, Pro-Dex's price-to-earnings ratio is 24.83x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.77x versus 36.22x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.77x 24.83x $16.8M $2M
    VNRX
    VolitionRX
    36.22x -- $474.5K -$5.8M
  • Which has Higher Returns PDEX or VTAK?

    Catheter Precision has a net margin of 12.15% compared to Pro-Dex's net margin of -4291.67%. Pro-Dex's return on equity of 21.59% beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    30.2% $0.61 $48.2M
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About PDEX or VTAK?

    Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 8.74%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 419.62%. Given that Catheter Precision has higher upside potential than Pro-Dex, analysts believe Catheter Precision is more attractive than Pro-Dex.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    VTAK
    Catheter Precision
    0 0 0
  • Is PDEX or VTAK More Risky?

    Pro-Dex has a beta of 0.682, which suggesting that the stock is 31.755% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.541, suggesting its less volatile than the S&P 500 by 154.132%.

  • Which is a Better Dividend Stock PDEX or VTAK?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PDEX or VTAK?

    Pro-Dex quarterly revenues are $16.8M, which are larger than Catheter Precision quarterly revenues of $96K. Pro-Dex's net income of $2M is higher than Catheter Precision's net income of -$4.1M. Notably, Pro-Dex's price-to-earnings ratio is 24.83x while Catheter Precision's PE ratio is 0.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.77x versus 1.03x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.77x 24.83x $16.8M $2M
    VTAK
    Catheter Precision
    1.03x 0.44x $96K -$4.1M
  • Which has Higher Returns PDEX or WST?

    West Pharmaceutical Services has a net margin of 12.15% compared to Pro-Dex's net margin of 17.38%. Pro-Dex's return on equity of 21.59% beat West Pharmaceutical Services's return on equity of 18.15%.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    30.2% $0.61 $48.2M
    WST
    West Pharmaceutical Services
    36.54% $1.78 $2.9B
  • What do Analysts Say About PDEX or WST?

    Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 8.74%. On the other hand West Pharmaceutical Services has an analysts' consensus of $286.12 which suggests that it could grow by 24.34%. Given that West Pharmaceutical Services has higher upside potential than Pro-Dex, analysts believe West Pharmaceutical Services is more attractive than Pro-Dex.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    WST
    West Pharmaceutical Services
    7 2 0
  • Is PDEX or WST More Risky?

    Pro-Dex has a beta of 0.682, which suggesting that the stock is 31.755% less volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.088, suggesting its more volatile than the S&P 500 by 8.847%.

  • Which is a Better Dividend Stock PDEX or WST?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services offers a yield of 0.36% to investors and pays a quarterly dividend of $0.21 per share. Pro-Dex pays -- of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios PDEX or WST?

    Pro-Dex quarterly revenues are $16.8M, which are smaller than West Pharmaceutical Services quarterly revenues of $748.8M. Pro-Dex's net income of $2M is lower than West Pharmaceutical Services's net income of $130.1M. Notably, Pro-Dex's price-to-earnings ratio is 24.83x while West Pharmaceutical Services's PE ratio is 34.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.77x versus 5.86x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.77x 24.83x $16.8M $2M
    WST
    West Pharmaceutical Services
    5.86x 34.40x $748.8M $130.1M
  • Which has Higher Returns PDEX or XTNT?

    Xtant Medical Holdings has a net margin of 12.15% compared to Pro-Dex's net margin of -10.04%. Pro-Dex's return on equity of 21.59% beat Xtant Medical Holdings's return on equity of -35.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    PDEX
    Pro-Dex
    30.2% $0.61 $48.2M
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
  • What do Analysts Say About PDEX or XTNT?

    Pro-Dex has a consensus price target of $54.00, signalling upside risk potential of 8.74%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 264.58%. Given that Xtant Medical Holdings has higher upside potential than Pro-Dex, analysts believe Xtant Medical Holdings is more attractive than Pro-Dex.

    Company Buy Ratings Hold Ratings Sell Ratings
    PDEX
    Pro-Dex
    1 0 0
    XTNT
    Xtant Medical Holdings
    2 0 0
  • Is PDEX or XTNT More Risky?

    Pro-Dex has a beta of 0.682, which suggesting that the stock is 31.755% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

  • Which is a Better Dividend Stock PDEX or XTNT?

    Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PDEX or XTNT?

    Pro-Dex quarterly revenues are $16.8M, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Pro-Dex's net income of $2M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Pro-Dex's price-to-earnings ratio is 24.83x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 2.77x versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PDEX
    Pro-Dex
    2.77x 24.83x $16.8M $2M
    XTNT
    Xtant Medical Holdings
    0.55x -- $31.5M -$3.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock